Cargando…

The Clinical and Immunological Activity Depending on the Presence of Interferon γ in Primary Sjögren’s Syndrome—A Pilot Study

The upregulation of IFN pathways and their stimulated genes is associated with primary Sjögren’s syndrome (pSS). The recent studies also indicate the involvement of interferon γ (IFNγ) in the pathogenesis of pSS. The study aimed to assess the clinical and immunological activity depending on the conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sebastian, Agata, Madej, Marta, Sebastian, Maciej, Łuczak, Anna, Gajdanowicz, Paweł, Zemelka-Wiącek, Magdalena, Wiland, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745422/
https://www.ncbi.nlm.nih.gov/pubmed/35011744
http://dx.doi.org/10.3390/jcm11010003
_version_ 1784630340865753088
author Sebastian, Agata
Madej, Marta
Sebastian, Maciej
Łuczak, Anna
Gajdanowicz, Paweł
Zemelka-Wiącek, Magdalena
Wiland, Piotr
author_facet Sebastian, Agata
Madej, Marta
Sebastian, Maciej
Łuczak, Anna
Gajdanowicz, Paweł
Zemelka-Wiącek, Magdalena
Wiland, Piotr
author_sort Sebastian, Agata
collection PubMed
description The upregulation of IFN pathways and their stimulated genes is associated with primary Sjögren’s syndrome (pSS). The recent studies also indicate the involvement of interferon γ (IFNγ) in the pathogenesis of pSS. The study aimed to assess the clinical and immunological activity depending on the concentration of IFNγ in the peripheral blood in pSS patients. Methods: The study group consisted of patients over 18 years of age with a confirmed diagnosis of pSS. Based on the collected data, disease activity was assessed using the EULAR Sjögren’s syndrome disease activity index (ESSDAI) and the EULAR Sjögren’s syndrome patient reported index (ESSPRI). Results: Among 40 pSS patients, 33 (82%) showed increased levels of IFNγ. The group with positive IFNγ was younger (43 years) than the group with negative IFNγ (57 years) (p < 0.05). In the positive IFNγ group, the time to diagnosis was shorter (p < 0.05). There was a difference in ESSDAI among patients with and without IFNγ (p < 0.05). There were no differences between the groups in ESSPRI and the presence of cryoglobulins, specific anti-SSA, and anti-SSB antibodies and in C3 and C4 hypocomplementemia. RF occurred in both groups with a similar frequency (p = 0.6), but in patients with IFNγ presence, significantly higher RF titers were observed (34.9 vs. 10.5; p < 0.05). Conclusion: In the group of patients with positive IFNγ, the mean value of RF and ESSDAI was higher. This group was also younger than patients with pSS without IFNγ.
format Online
Article
Text
id pubmed-8745422
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87454222022-01-11 The Clinical and Immunological Activity Depending on the Presence of Interferon γ in Primary Sjögren’s Syndrome—A Pilot Study Sebastian, Agata Madej, Marta Sebastian, Maciej Łuczak, Anna Gajdanowicz, Paweł Zemelka-Wiącek, Magdalena Wiland, Piotr J Clin Med Article The upregulation of IFN pathways and their stimulated genes is associated with primary Sjögren’s syndrome (pSS). The recent studies also indicate the involvement of interferon γ (IFNγ) in the pathogenesis of pSS. The study aimed to assess the clinical and immunological activity depending on the concentration of IFNγ in the peripheral blood in pSS patients. Methods: The study group consisted of patients over 18 years of age with a confirmed diagnosis of pSS. Based on the collected data, disease activity was assessed using the EULAR Sjögren’s syndrome disease activity index (ESSDAI) and the EULAR Sjögren’s syndrome patient reported index (ESSPRI). Results: Among 40 pSS patients, 33 (82%) showed increased levels of IFNγ. The group with positive IFNγ was younger (43 years) than the group with negative IFNγ (57 years) (p < 0.05). In the positive IFNγ group, the time to diagnosis was shorter (p < 0.05). There was a difference in ESSDAI among patients with and without IFNγ (p < 0.05). There were no differences between the groups in ESSPRI and the presence of cryoglobulins, specific anti-SSA, and anti-SSB antibodies and in C3 and C4 hypocomplementemia. RF occurred in both groups with a similar frequency (p = 0.6), but in patients with IFNγ presence, significantly higher RF titers were observed (34.9 vs. 10.5; p < 0.05). Conclusion: In the group of patients with positive IFNγ, the mean value of RF and ESSDAI was higher. This group was also younger than patients with pSS without IFNγ. MDPI 2021-12-21 /pmc/articles/PMC8745422/ /pubmed/35011744 http://dx.doi.org/10.3390/jcm11010003 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sebastian, Agata
Madej, Marta
Sebastian, Maciej
Łuczak, Anna
Gajdanowicz, Paweł
Zemelka-Wiącek, Magdalena
Wiland, Piotr
The Clinical and Immunological Activity Depending on the Presence of Interferon γ in Primary Sjögren’s Syndrome—A Pilot Study
title The Clinical and Immunological Activity Depending on the Presence of Interferon γ in Primary Sjögren’s Syndrome—A Pilot Study
title_full The Clinical and Immunological Activity Depending on the Presence of Interferon γ in Primary Sjögren’s Syndrome—A Pilot Study
title_fullStr The Clinical and Immunological Activity Depending on the Presence of Interferon γ in Primary Sjögren’s Syndrome—A Pilot Study
title_full_unstemmed The Clinical and Immunological Activity Depending on the Presence of Interferon γ in Primary Sjögren’s Syndrome—A Pilot Study
title_short The Clinical and Immunological Activity Depending on the Presence of Interferon γ in Primary Sjögren’s Syndrome—A Pilot Study
title_sort clinical and immunological activity depending on the presence of interferon γ in primary sjögren’s syndrome—a pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745422/
https://www.ncbi.nlm.nih.gov/pubmed/35011744
http://dx.doi.org/10.3390/jcm11010003
work_keys_str_mv AT sebastianagata theclinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT madejmarta theclinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT sebastianmaciej theclinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT łuczakanna theclinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT gajdanowiczpaweł theclinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT zemelkawiacekmagdalena theclinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT wilandpiotr theclinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT sebastianagata clinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT madejmarta clinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT sebastianmaciej clinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT łuczakanna clinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT gajdanowiczpaweł clinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT zemelkawiacekmagdalena clinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy
AT wilandpiotr clinicalandimmunologicalactivitydependingonthepresenceofinterferonginprimarysjogrenssyndromeapilotstudy